22nd Century Group Q3 2026 Earnings Date & Estimates

22nd Century Group (NASDAQ:XXII). was a biotechnology company focused on developing tobacco products with reduced nicotine content. Its research centered on genetically modified tobacco plants and cigarette formulations designed to lower nicotine exposure and support smoking cessation or harm-reduction efforts.

The company’s principal product was VLN cigarettes, which were made with very low nicotine tobacco and marketed as containing substantially less nicotine than conventional cigarettes. 22nd Century also historically developed and commercialized other reduced-nicotine cigarette products, including Quest, and pursued applications of its plant-science technology in the tobacco and cannabinoid sectors.

Based in the United States, 22nd Century Group sought to serve the U.S. tobacco market and explored international opportunities for its reduced-nicotine products. The company later experienced significant financial and operational difficulties, including a Chapter 11 bankruptcy filing in 2024. Its business and public-market status may therefore differ materially from historical company descriptions.